Voluntary nationwide recall: Betaxolol

Oct. 2023Pharmacy Updates
KVK-Tech Inc. is recalling one lot of Betaxolol tablets, USP 10 mg. This drug is used for the treatment of hypertension (high blood pressure).

KVK-Tech Inc. is recalling one lot of this drug (batch number 17853A) as a precautionary measure because a single Oxycodone HCl tablet 5 mg tablet ws found in one batch of the packaging. Betaxolol tablets have a debossed “K” above bisect “13” on one side and plain on the other side, which looks similar to Oxycodone HCL 5 mg tablets. Inadvertent exposure to a controlled substance, such as oxycodone, in specific patient populations is likely to result in significant slowing in breathing, known as respiratory depression, which is a serious health risk.

As of Sept. 29, 2023, there have been no reports of adverse events related to this recall.

Please see the table below to determine if your product has been recalled:

Product name: Betaxolol tablets USP 10 MG (NDC 10702-0013-01)
Lot number: 17853A
Expiry date:06/2027

If you have Betaxolol 10 mg tablets from this lot, you should stop using/return to place of purchase/discard.

To learn more about this recall, you can take one or more of the steps below.
  • Talk to your doctor or pharmacist.
  • Call KVK-Tech Inc. at 215-579-1842 Ext: 6002. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 6 p.m. EST.
  • Visit the FDA website at upmchp.us/betaxolol-drugrecall.

Recent Announcements

CME/CEU Webinar: Bright Beginnings: The Role of Medical and Dental Providers in Early Oral Health

Please join us for a live, CME-accredited and CEU-accredited webinar on Monday, Aug. 24 from noon to 1 p.m., that will educate providers on the importance of early childhood oral health.
Jun. 2026Education/Webinars

Provider OnLine Multi-Factor Authentication Enhancements coming soon

Microsoft changes and security enhancements will soon require Provider OnLine users to complete multi-factor authentication (MFA) each time they log in to access the portal. MFA is a security feature that adds an extra layer of protection by requiring more than just a password. This MFA requirement is expected to take effect on June 25, 2026.
Jun. 2026Important Notices

Voluntary nationwide recall: Dexcom G7 sensors (June 2026)

Dexcom, Inc. is recalling two lots of Dexcom G7 sensors. Dexcom G7 sensors are used to monitor blood glucose levels as part of the Dexcom Glucose Monitoring system.
Jun. 2026Pharmacy Updates